Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 1/2005

01-08-2005 | Research Article

Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma

Authors: Mohammad Reza Abbaszadegan, MT (ASCP), PhD, Hamid Reza Raziee, Kamran Ghafarzadegan, Mohammad Taghi Shakeri, Sima Afsharnezhad, Mohammad Reza Ghavamnasiry

Published in: Journal of Gastrointestinal Cancer | Issue 1/2005

Login to get access
Metadata
Title
Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma
Authors
Mohammad Reza Abbaszadegan, MT (ASCP), PhD
Hamid Reza Raziee
Kamran Ghafarzadegan
Mohammad Taghi Shakeri
Sima Afsharnezhad
Mohammad Reza Ghavamnasiry
Publication date
01-08-2005
Publisher
Humana Press
Published in
Journal of Gastrointestinal Cancer / Issue 1/2005
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1385/IJGC:36:1:047

Other articles of this Issue 1/2005

Journal of Gastrointestinal Cancer 1/2005 Go to the issue

Research Article

Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines

Comment

Metastasis to appendix from lung adenocarcinoma

Review

State of the art: Gastrointestinal malignancies in the human immunodeficiency virus (HIV) population

Research Article

Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy

Research Article

Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation

Case Report

Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits